3-M Syndrome: Comprehensive Research Report

1. Disease Information

Overview. 3-M syndrome (also written "3M syndrome," "Miller-McKusick-Malvaux syndrome," "Le Merrer syndrome," or "Gloomy face syndrome") is a rare autosomal recessive primordial growth disorder — meaning growth restriction begins prenatally and persists throughout life without a "catch-up" phase — characterized by severe pre- and postnatal growth deficiency, a distinctive facial gestalt, characteristic skeletal/radiographic findings, and normal intelligence. The name derives from the surnames of the three physicians (Miller, McKusick, Malvaux) who first described it in 1975.

Key identifiers: - OMIM: 3M syndrome 1 (#273750, CUL7), 3M syndrome 2 (#612921, OBSL1), 3M syndrome 3 (#614205, CCDC8) OMIM #273750; OMIM #612921; OMIM #614205 - Orphanet: ORPHA2616 (Orphanet: 3M syndrome) - MONDO: MONDO:0007477 (3M syndrome 1); related MONDO terms exist per subtype - Disease Ontology: DOID:0060241 - GeneReviews: NBK1481 (Cormier-Daire, Huber, et al., updated periodically) - GTR/MeSH/ICD: Listed under primordial dwarfism / short stature syndromes; no dedicated ICD-10-CM code beyond the general short-stature syndrome category

Synonyms: 3M syndrome; Miller-McKusick-Malvaux syndrome; Le Merrer syndrome; Gloomy face syndrome (historical, now discouraged); Dolichospondylic dysplasia; Yakut short stature syndrome (population-specific CUL7 founder-variant form).

Data derivation: Information is drawn predominantly from aggregated case-series/cohort literature (fewer than ~250 molecularly confirmed cases reported worldwide as of 2025) rather than large-scale EHR/registry data, reflecting the disorder's rarity. GeneReviews and the recent 2025 natural-history literature review (217 pooled cases from 36 publications) are the most authoritative aggregate sources.

2. Etiology

Disease causal factors — genetic. 3-M syndrome is caused by biallelic (homozygous or compound heterozygous) loss-of-function variants in one of three genes encoding components of a single molecular complex:

Approximately 1% of clinically diagnosed cases remain molecularly unresolved, suggesting additional causative genes or loci may exist (GeneReviews NBK1481).

• CUL7 variants: predominance of null variants (nonsense, splice-site; missense also frequent); ~50% of pathogenic variants localize to the cullin domain critical for ROC1 anchoring.
• OBSL1 variants: most pathogenic variants occur within the first 8 exons, affecting all known isoforms, predominantly loss-of-function.
• CCDC8: a single-exon gene; pathogenic variants lead to truncation and loss of function.

Founder variants (population-specific risk factors): - Yakut population (Siberia): CUL7 c.4581dupT (also reported as 4582_4583insT), described by Maksimova et al. 2007, associated with a distinctive phenotype of high neonatal respiratory distress but comparatively few bone abnormalities (PMC2652813). - Maghrebian/Tunisian population: CUL7 c.4451_4452delTG. - Turkish population: OBSL1 c.1273dupA (emerging founder variant).

Risk factors: - Genetic: Consanguinity substantially raises risk given the autosomal recessive inheritance and regional founder alleles; carrier parents (heterozygotes) are asymptomatic. - Environmental: No environmental, toxin, infectious, or lifestyle risk factors have been identified — this is a purely monogenic Mendelian disorder. - Modifier genes: None formally established, though phenotypic variability (e.g., milder stature in CCDC8-related disease vs. more severe in CUL7-related disease) suggests gene-specific and possibly allele-specific modulation of severity.

Protective factors: None described; this is a fully penetrant recessive disorder once biallelic pathogenic variants are present.

Gene-environment interactions: Not applicable/not reported — no environmental modifiers of penetrance or expressivity have been documented in the literature.

3. Phenotypes

Growth phenotype

• Severe pre- and postnatal growth deficiency: final adult height typically ~5 SD below the mean (range roughly 115–150 cm in adults). Birth length typically 40–42 cm with normal head circumference for gestational age (giving the appearance of relative macrocephaly).
• No catch-up growth occurs; short stature is proportionate. HPO: HP:0004322 (Short stature), HP:0001511 (Intrauterine growth retardation).

Craniofacial features

Characteristic facies including: relative macrocephaly (HP:0004482 / HP:0000256 macrocephaly-adjacent terms), dolichocephaly (HP:0000268), triangular face (HP:0000325), midface retrusion (HP:0011800), thick eyebrows (HP:0000574), fleshy/bulbous nasal tip (HP:0000455-adjacent), long philtrum (HP:0000343), thick vermilion of upper and lower lips (HP:0012471), pointed chin (HP:0000307). Infants may show facial nevus simplex and infraorbital fullness that fade with age. Facial appearance is most diagnostic in infancy and becomes progressively subtler through childhood into adolescence, per a 2025 natural-history review of 217 cases (Ital J Pediatr, PMID 41437277, DOI 10.1186/s13052-025-02172-8).

Musculoskeletal features

Short broad neck, prominent trapezii, pectus carinatum/excavatum (HP:0000768/HP:0000767), short thorax, square shoulders, winged scapulae, thoracic kyphoscoliosis (HP:0002751), hyperlordosis (HP:0002938), spina bifida occulta, clinodactyly of the fifth finger (HP:0004209), joint hypermobility (HP:0001382), hip dislocation, prominent heels, pes planus (HP:0001763).

Radiographic (skeletal) hallmark features

• Slender long bones with diaphyseal constriction and flared metaphyses — the primary distinguishing radiologic sign.
• Tall vertebral bodies with reduced anteroposterior and transverse diameters, especially lumbar.
• Elevated metacarpal and vertebral indices.
• Small pelvic bones. These become "increasingly vague" with age, per the 2025 natural-history review, so radiographic diagnosis is most reliable in infancy.

Neurodevelopmental

Normal intelligence is a defining and diagnostically important feature that distinguishes 3-M syndrome from many other severe short-stature/primordial-dwarfism syndromes (e.g., Seckel syndrome, microcephalic primordial dwarfism).

Endocrine/reproductive

Males may have hypogonadism and occasionally hypospadias (HP:0000047); a 2024 JCEM Case Reports paper documented a CUL7-variant male with bifid scrotum and perineal hypospadias at birth, spontaneous but incomplete pubertal maturation, and progressive gonadal failure in adolescence (declining testicular volume, rising gonadotropins, low-normal testosterone) (PMID 38847008, PMC11154130). Female gonadal function appears normal. Endocrine (thyroid, adrenal) function is otherwise generally normal.

Cardiac

Aortic root dilatation reported in some individuals — a rationale for periodic echocardiographic surveillance.

Respiratory

Some neonates, particularly in the Yakut founder-variant population, experience significant neonatal respiratory distress (~41% in that population), sometimes requiring NICU care.

Quality of life

Not formally quantified with standardized instruments (EQ-5D/SF-36) in the literature reviewed; qualitatively, impact centers on short-stature-related psychosocial and functional issues (adaptive equipment needs, orthopedic complications) rather than cognitive/behavioral burden, since intelligence and daily function are largely preserved.

4. Genetic/Molecular Information

Causal genes: CUL7 (HGNC:16290, OMIM 609577), OBSL1 (HGNC:15738, OMIM 610991), CCDC8 (HGNC:17086, OMIM *614145).

Pathogenic variant classification: Per ACMG/AMP framework, disease-causing alleles are classified as pathogenic/likely pathogenic biallelic loss-of-function or damaging missense variants; heterozygous carriers are unaffected. ClinVar/ClinGen entries exist for known recurrent and founder variants.

Variant types: - Nonsense, frameshift, and canonical splice-site variants predominate for CUL7 and OBSL1 (loss-of-function mechanism). - Missense variants also occur in CUL7, frequently clustering in the cullin domain required for ROC1 (RBX1) anchoring within the SCF-like complex. - CCDC8, being single-exon, is disrupted almost exclusively by truncating variants causing loss of function.

Allele frequency: No individual pathogenic variant reaches appreciable frequency in general population databases (gnomAD) outside specific founder populations (Yakut, Maghrebian/Tunisian, Turkish), consistent with an ultra-rare recessive disorder.

Origin: Germline, biallelic — not somatic; both alleles inherited from heterozygous, unaffected parents (or occasionally uniparental disomy/de novo events, though these are not prominently reported for this condition).

Functional consequence — molecular mechanism: CUL7 is a member of the Cullin family and forms the scaffold of an SCF-like (Skp1–Cullin–F-box) E3 ubiquitin ligase complex localized to the Golgi apparatus. This complex: - Physically interacts with OBSL1 and CCDC8 to form the "3-M E3 complex," which regulates microtubule dynamics and ubiquitinates the membrane-associated protein LL5β, impacting cell migration and cytoskeletal regulation (Hanson et al. 2009, Am J Hum Genet, PMC2694976; PMID 19481195). - Is implicated in proteasomal degradation of IRS-1 (insulin receptor substrate-1) and cyclin D1. CUL7 interacts with IRS-1, a downstream signaling node shared by insulin, IGF-1, and GH receptor pathways. Loss of CUL7 function leads to IRS-1 accumulation (impaired proteasomal turnover), and downstream reduced IGF-1-mediated activation of Akt and reduced cell proliferation (Endocrine Abstracts EA0021P232). - Loss of CUL7 also reduces OBSL1 transcription, tying the three genes into a single interdependent pathway — consistent with all three genes producing a convergent, largely indistinguishable phenotype (CUL7- and OBSL1-related disease are "clinically and radiographically indistinguishable," per GeneReviews, though CUL7-related disease tends to produce shorter final stature). - A separate mechanistic axis: 3-M fibroblasts show an epigenetic gene-expression signature of reduced IGF2 expression and increased H19 expression, resembling the imprinting profile of Silver-Russell syndrome, with markedly reduced IGF-II secretion in conditioned culture medium (10.2±2.9 ng/mL control vs. 0.6±0.9 ng/mL 3-M fibroblasts, P<0.01) — implicating IGF2 silencing as a contributing, gene-network-level (not primary genetic-imprinting) mechanism (Meyer et al. 2013, Endocr Connect, PMID 24148222, PMC3847915).

Modifier genes: None formally established; phenotype-genotype correlation is largely gene-specific (CUL7 > OBSL1 > CCDC8 severity gradient) rather than driven by known secondary modifiers.

Epigenetic information: The IGF2/H19 imprinting-like expression signature above is the principal epigenetic finding; it appears to be a downstream transcriptional consequence of E3-complex disruption rather than a primary imprinting defect.

Chromosomal abnormalities: 3-M syndrome is not caused by large structural chromosomal rearrangements; it is a single-gene (biallelic small-variant) disorder. No characteristic CNV/translocation etiology has been reported.

5. Environmental Information

3-M syndrome is a monogenic Mendelian disorder with no identified environmental, toxin, infectious, or lifestyle contributing factors. It is not associated with teratogen exposure, maternal illness, or infectious triggers. The only population-level "risk factor" beyond genetics is consanguinity, which increases the probability of biallelic inheritance of a rare recessive allele, and geographic/ethnic founder-variant enrichment (Yakut, Maghrebian, Turkish populations).

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream):

1. Molecular trigger: Biallelic loss-of-function variant in CUL7, OBSL1, or CCDC8 → loss of function of one component of the Golgi-localized 3-M E3 ubiquitin ligase complex.
2. Complex disruption: CUL7, OBSL1, and CCDC8 normally physically interact to form the joint 3-M E3 complex, which is critical for microtubule regulation and ubiquitination of the membrane-associated protein LL5β (cell migration regulator). Loss of any one component destabilizes the complex.
3. Impaired proteostasis of growth-signaling intermediates: Failure of ubiquitin-mediated proteasomal degradation of IRS-1 (and cyclin D1) → IRS-1 accumulation.
4. Blunted IGF-1/insulin/GH signal transduction: Because IRS-1 is a shared downstream node of insulin, IGF-1, and GH receptor pathways, its dysregulated turnover produces reduced IGF-1-mediated Akt activation and reduced cellular proliferative response to growth-factor stimulation.
5. Cell-cycle/cytoskeletal defects: Mitotic and cytokinesis abnormalities from loss of CUL7 function are proposed contributors to short stature; reduced OBSL1 transcription follows loss of CUL7, reinforcing pathway interdependence.
6. Epigenetic-level convergence: A gene-expression signature of reduced IGF2 and elevated H19 (Silver-Russell-like) further suppresses IGF-II bioavailability, compounding the growth-signaling deficit.
7. Tissue-level consequence — growth plate dysfunction: Cartilage-specific Cul7 knockout mice show abnormally short/deformed limbs, thickened growth plates, disorganized chondrocyte columns, decreased proliferative-zone cell numbers, and disordered trabecular bone at the metaphysis — implicating both chondrocyte proliferation defects and disrupted endochondral ossification as the proximate tissue mechanism of skeletal growth failure (Longitudinal skeletal growth study, PMID 38367951, ScienceDirect).
8. Organism-level phenotype: Severe proportionate pre-/postnatal growth restriction, characteristic facial dysmorphism, skeletal (long-bone/vertebral) abnormalities, and (in a subset) gonadal, cardiac, and respiratory involvement, with sparing of cognitive development.

Molecular pathways involved: Ubiquitin-proteasome system (SCF/Cullin-RING E3 ligase pathway); insulin/IGF-1/GH-IRS1-Akt signaling axis; microtubule/cytoskeletal regulation via LL5β.

Cellular processes: Impaired cell proliferation, disrupted mitosis/cytokinesis, altered cell migration (cytoskeletal), disrupted chondrocyte proliferation and endochondral ossification.

Protein dysfunction: Loss-of-function of CUL7 (scaffold protein of Golgi-localized E3 ligase), OBSL1 (cytoskeletal adaptor), CCDC8 (coiled-coil complex partner); consequent failure of substrate (IRS-1, cyclin D1, LL5β) ubiquitination/degradation.

Suggested ontology terms: - GO (biological process): GO:0016567 (protein ubiquitination), GO:0043161 (proteasome-mediated ubiquitin-dependent protein catabolic process), GO:0043410 (positive regulation of MAPK cascade)/IGF signaling-related terms, GO:0001501 (skeletal system development), GO:0060350 (endochondral bone morphogenesis) - GO (molecular function): GO:0031625 (ubiquitin protein ligase binding), GO:0004842 (ubiquitin-protein transferase activity) - CL (cell types): CL:0000138 (chondrocyte), CL:0000057 (fibroblast, used in in vitro studies) - UBERON: UBERON:0002102 (growth plate cartilage), UBERON:0001474 (bone element)

7. Anatomical Structures Affected

Organ/system level: - Skeletal system (primary): long bones, vertebral column, pelvis, ribs, hands/feet — UBERON:0001434 (skeletal system) - Craniofacial skeleton and soft tissue: skull shape, facial structure — UBERON:0000033 (head) - Reproductive system (males): testes, scrotum, penile/urethral development (hypospadias) — UBERON:0000473 (testis) - Cardiovascular system: aortic root — UBERON:0002049 (aorta) - Respiratory system: neonatal lung maturation/distress in some populations — UBERON:0002048 (lung) - CNS: spared (normal intelligence)

Tissue/cell level: Growth plate chondrocytes (proliferative zone), cortical/trabecular bone, dermal fibroblasts (used for functional IGF2/H19 studies), Golgi-associated cellular machinery broadly (since CUL7 localizes to the Golgi apparatus).

Subcellular level: Golgi apparatus (site of the 3-M E3 ligase complex) — GO:0005794 (Golgi apparatus); microtubule cytoskeleton — GO:0005874 (microtubule); ubiquitin-proteasome machinery — GO:0000502 (proteasome complex).

Localization/laterality: Findings are generally bilateral and symmetric (proportionate short stature, symmetric limb involvement) — this symmetry is a key differentiator from Silver-Russell syndrome, which classically shows limb-length asymmetry.

8. Temporal Development

Onset: Prenatal — intrauterine growth restriction is evident before birth (low birth weight/length with normal-for-age head circumference), making this a primordial (prenatal-onset) growth disorder rather than a postnatal-onset condition.

Progression: Persistent, non-progressive, lifelong short stature without catch-up growth. The disorder is generally stable rather than degenerative — final adult height is reached without further mechanistic deterioration, though secondary orthopedic (kyphoscoliosis, joint laxity) and endocrine (pubertal, gonadal) complications can evolve over time.

Phenotype evolution with age (per the 2025 natural-history review of 217 cases, PMID 41437277): - Infancy is the period of clearest diagnostic signal — short length/thorax, protuberant abdomen, prominent heels, bulbous/fleshy nasal tip, and the most distinct radiographic long-bone/vertebral findings. - Childhood through adolescence: most dysmorphic and radiographic features progressively attenuate/become "increasingly vague"; short stature and the characteristic nasal appearance persist as the most durable diagnostic clues. - Puberty/adulthood: some males show initially normal pubertal onset followed by secondary (progressive) gonadal failure in adolescence/young adulthood (declining testicular volume, rising gonadotropins) — a later-emerging, evolving feature rather than a static congenital one.

Critical periods: Infancy/early childhood is the critical window for clinical/radiographic diagnosis and for initiating growth hormone trials, given diminishing diagnostic specificity of physical signs with age.

9. Inheritance and Population

Epidemiology: - Prevalence: Not formally established; fewer than ~250 molecularly confirmed cases reported in the literature worldwide since the first description in 1975 (GeneReviews NBK1481); Orphanet lists it as "very rare" with prevalence unknown/<1/1,000,000. - Incidence: Not reported at a population level (too rare for standard surveillance-based incidence estimation).

Inheritance pattern: Autosomal recessive for all three subtypes (3M1/CUL7, 3M2/OBSL1, 3M3/CCDC8). Sibling recurrence risk when both parents are carriers: 25% affected, 50% carrier, 25% unaffected/non-carrier.

Penetrance: Complete (biallelic pathogenic variants are consistently associated with the phenotype).

Expressivity: Variable — facial/skeletal severity and final height vary by gene (CUL7 generally associated with the shortest stature; CCDC8-related disease tends to be milder with relatively higher final height) and to some extent by specific allele (e.g., the Yakut CUL7 founder variant produces a distinct sub-phenotype with high neonatal respiratory distress but comparatively fewer bone abnormalities).

Genetic anticipation: Not applicable/not reported (not a repeat-expansion disorder).

Germline mosaicism: Not specifically documented in the reviewed literature, though standard recessive-disorder recurrence counseling applies.

Founder effects: - Yakut (Sakha) population, Siberia: CUL7 c.4581dupT — described in 43 affected individuals (Maksimova et al. 2007, PMC2652813); associated with high neonatal respiratory distress (~41%) and fewer skeletal anomalies than typical CUL7-related disease. - Maghrebian/Tunisian population: CUL7 c.4451_4452delTG. - Turkish population: OBSL1 c.1273dupA (emerging founder allele).

Consanguinity role: Strongly associated with increased case frequency, as expected for an ultra-rare autosomal recessive disorder; many reported cohorts (e.g., recent Chinese and Middle Eastern case series) note parental consanguinity.

Carrier frequency: Not established at a population level outside founder populations.

Population demographics: Reported cases span diverse ethnic groups (European, Middle Eastern/Maghrebian, East Asian [Chinese, Japanese], Siberian/Yakut, Turkish), consistent with panethnic occurrence with regional founder-variant clustering. No formal sex-ratio skew is reported (autosomal recessive, so no inherent sex bias, aside from male-specific gonadal manifestations being clinically more apparent in males).

10. Diagnostics

Diagnostic criteria (GeneReviews): Diagnosis established in a proband with prenatal-onset persistent growth deficiency plus characteristic clinical and radiographic features, and/or identification of biallelic pathogenic variants in CCDC8, CUL7, or OBSL1 by molecular genetic testing. No formally published consensus clinical scoring criteria exist.

Clinical tests: - Imaging: Skeletal radiographic survey — long bones (slender diaphyses, flared metaphyses), spine (tall vertebral bodies), pelvis (small pelvic bones); echocardiography for aortic root assessment. - Laboratory: IGF-1 levels (monitored during GH trials); gonadotropin/testosterone panel in pubertal/adult males for hypogonadism surveillance. - Prenatal ultrasound: Short long bones and other skeletal findings can be detected as early as 24 weeks' gestation, though findings are not pathognomonic on their own.

Genetic testing: - Recommended approach: multigene panel covering CUL7, OBSL1, CCDC8 (and relevant differential-diagnosis genes), or exome/genome sequencing given phenotypic overlap with other growth-restriction syndromes. - Single-gene sequential testing (starting with CUL7, the most frequently implicated gene) is an alternative in resource-limited settings or when a founder variant is suspected by ancestry. - Prenatal and preimplantation genetic testing are available once familial pathogenic variants are identified (demonstrated in a 2023 Chinese family case, PMC10767403).

Clinical criteria / differential diagnosis (per GeneReviews): - Silver-Russell syndrome: often shows limb-length asymmetry and relative macrocephaly at birth; lacks the classic 3-M long-bone/vertebral radiologic signature; notably, 3-M syndrome shares an IGF2/H19 expression signature with SRS at the molecular level despite distinct genetic causes. - Mulibrey nanism: less severe IUGR; distinct facial gestalt (high forehead, "pseudohydrocephalic" skull). - IGF1R haploinsufficiency/deficiency: microcephaly and intellectual disability common in severe cases (contrasts with normal head size/intelligence in 3-M). - Dubowitz syndrome: microcephaly, eczema, intellectual disability. - Fetal alcohol syndrome: acquired, with microcephaly and nail hypoplasia — important to exclude given overlapping growth restriction/facial features.

Screening: No population-based newborn screening program exists (disorder too rare and non-treatable via early biochemical intervention); diagnosis is clinically/radiographically or genetically triggered rather than screened.

11. Outcome/Prognosis

• Survival/mortality: Life expectancy is generally normal. No characteristic disease-specific mortality has been documented outside of population-specific neonatal respiratory distress risk (e.g., Yakut founder variant) and rare complete-knockout-lethal equivalents in constitutive animal models (not applicable to human heterozygous-viable genotypes, since humans with the disease are, by definition, live-born survivors of hypomorphic/partial-loss-of-function alleles).
• Morbidity: Primarily orthopedic (kyphoscoliosis, hip dysplasia/dislocation, joint hypermobility-related complications, potential early arthritis), endocrine (progressive gonadal failure in some males), and cardiovascular (aortic root dilatation) morbidity, layered onto lifelong short stature.
• Cognitive/functional outcome: Normal intelligence and generally preserved functional independence, distinguishing 3-M syndrome prognostically from many other severe growth-restriction syndromes.
• Complications: Neonatal respiratory distress (population-dependent), hip dislocation, scoliosis, joint laxity/early arthritis risk, hypospadias (surgical correction), progressive hypogonadism in some males, aortic root dilation.
• Prognostic factors: Causal gene (CUL7 > OBSL1 > CCDC8 in terms of severity/short stature), specific founder variant (e.g., Yakut variant → higher respiratory risk), and timing/response to growth hormone trial.
• Recovery potential: Height deficit is not "recovered" — it is a fixed, non-progressive trait once adult stature is reached; management is supportive/adaptive rather than curative.

12. Treatment

Pharmacotherapy — Growth hormone (GH): - Standard of care approach: referral to pediatric endocrinology for a trial of recombinant human growth hormone, particularly in prepubertal children, with close monitoring of growth velocity and IGF-1 levels. - Response is variable: some children show meaningful improvement in growth velocity; others show poor response. A well-documented case (novel CUL7 mutation, associated with neonatal respiratory distress) showed a good response to GH therapy (PMID from PMC4418346, Endocrinol Diabetes Metab Case Rep); another 18-year follow-up case documented 3-M syndrome co-occurring with growth hormone deficiency responding to treatment (PMC3608257, Ital J Pediatr 2013). - One reported individual with CUL7-related disease treated with recombinant human IGF-1 showed a poor response and significant side effects — IGF-1 therapy is not generally favored. - NCIT term: NCIT:C15986 (Pharmacotherapy) as the general treatment_term, with growth hormone as therapeutic_agent (e.g., somatropin, CHEBI-bindable).

Surgical/interventional: - Orthopedic surgery for hip dysplasia/dislocation and progressive kyphoscoliosis (NCIT:C16186, Orthopedic Surgical Procedure). - Surgical limb lengthening is an option for selected patients seeking increased stature (NCIT:C15329, Surgical Procedure). - Urological surgery for hypospadias correction in affected males (NCIT:C15329).

Supportive/rehabilitative: - Physical therapy (NCIT:C15302) and occupational therapy to maximize function and address joint hypermobility/adaptive needs. - Environmental/community adaptations (adaptive equipment, community child-health services) for short stature.

Endocrine management: Monitoring and, where indicated, hormone replacement for males with progressive hypogonadism (testosterone/gonadotropin-guided management by endocrinology).

Surveillance/monitoring protocol (from GeneReviews):

Experimental/investigational: No gene therapy, RNA-based therapy, or targeted molecular therapy has been developed or trialed for 3-M syndrome; management remains supportive/symptomatic rather than mechanism-targeted, reflecting the structural (ubiquitin-ligase complex assembly) nature of the defect, which is not straightforwardly druggable. No relevant ClinicalTrials.gov interventional trials specific to 3-M syndrome were identified in this search.

Treatment outcomes / adverse events: GH therapy is generally well tolerated in the reported cases with variable efficacy; IGF-1 therapy in the one reported case caused significant side effects with poor efficacy.

13. Prevention

• Primary prevention: Not applicable in the traditional sense (no modifiable environmental cause); the only "primary prevention" lever is reproductive/genetic counseling for known carrier couples, particularly in consanguineous unions or founder-variant populations (Yakut, Maghrebian, Turkish).
• Secondary prevention (early detection): Prenatal ultrasound surveillance (skeletal findings detectable from ~24 weeks in at-risk pregnancies) and, where familial variants are known, prenatal diagnosis and preimplantation genetic testing (PGT) — demonstrated in a 2023 Chinese family case using novel biallelic CUL7 variants (PMC10767403).
• Genetic counseling: Central to prevention/family planning — carrier detection in relatives once the familial variant(s) are known; counseling on the 25% recurrence risk for future pregnancies of carrier couples; sibling evaluation for undiagnosed short stature.
• Screening programs: No population-based newborn or carrier screening program exists given extreme rarity, though targeted carrier screening is reasonable in founder populations with known high local carrier frequency.
• Tertiary prevention: Surveillance protocol above (orthopedic, cardiac, endocrine) aims to prevent/mitigate secondary complications (scoliosis progression, hip damage, aortic complications, missed hypogonadism) rather than the primary disease process.

14. Other Species / Natural Disease

Naturally occurring veterinary disease: - Sheep (Ovis aries): A recessively inherited disorder in Australian Poll Merino/Merino sheep called Brachygnathia, Cardiomegaly and Renal Hypoplasia Syndrome (BCRHS) was found to be caused by a frameshift variant in OBSL1 (p.(Val573Trpfs119)), representing a naturally occurring ovine model of human 3M syndrome-2. Identification enabled improved breeding management of the affected flock via carrier detection (BMC Genomic Data 2020; OMIA:001595-9940, "Growth disorder, syndromic, OBSL1-related," in Ovis aries*).

Comparative biology / model organisms: - Mouse (Mus musculus), Cul7 knockout: Constitutive Cul7−/− mice are perinatal lethal — severe growth retardation in late gestation and respiratory distress after birth; some models show abnormal bone mineralization, decreased body weight, and reduced bone mineral density; others show severe fetal growth restriction and perinatal death (multiple studies cited in PMC10423707 background). To circumvent lethality, a cartilage-specific conditional knockout (Cul7^fl/fl;Col2a1-CreERT2) was generated: these mice show short/deformed limbs, thickened growth plates, disorganized proliferative-zone chondrocyte columns, and disordered metaphyseal trabecular bone — implicating defective chondrocyte proliferation and endochondral ossification (PMID 38367951, ScienceDirect, "Longitudinal skeletal growth and growth plate morphological characteristics of chondro-tissue specific CUL7 knockout mice"). - Mouse, CCDC8 knockout: A 2023 study (Molecular Biomedicine, PMID 37574524, PMC10423707) established a Ccdc8−/− mouse model; knockout was highly lethal (only 4 live-born knockouts from 410 mice bred, <1% success rate), with placental developmental disorder, intrauterine growth retardation, intrauterine death, and perinatal death closely paralleling Cul7 knockout embryo phenotypes — supporting the shared-pathway model of CUL7/OBSL1/CCDC8 function. - OBSL1 knockout studies (Hanson et al. 2009, PMC2694976) established the direct physical and functional link between OBSL1 and the CUL7-containing E3 ligase complex, foundational to the current mechanistic model.

Cross-species relevance: These animal models (sheep OBSL1, mouse Cul7/Ccdc8) confirm cross-species conservation of the 3-M E3 complex's essential role in fetal/perinatal growth and support their use for mechanistic and (potentially) therapeutic research, though the severe perinatal lethality of constitutive knockouts limits their use to conditional/tissue-specific systems for postnatal phenotyping.

Zoonotic potential: None — this is a purely genetic (non-infectious) disorder; no transmission risk.

15. Model Organisms

Applications: These models collectively support study of (a) the shared CUL7-OBSL1-CCDC8 E3-ligase-complex biology, (b) chondrocyte/growth-plate-specific consequences of complex loss, (c) placental/perinatal growth-restriction mechanisms, and (d) potential future therapeutic-target validation (e.g., IGF-1/Akt pathway modulation), though no model has yet been used for interventional (drug) testing specific to 3-M syndrome in the literature surveyed.

Model limitations: Constitutive knockouts in mouse (Cul7, Ccdc8) are embryonic/perinatal lethal and thus do not recapitulate the live-born, postnatal phenotype seen in humans (who carry hypomorphic/partial-loss-of-function alleles rather than complete null states compatible only with lethality) — a clear human-model mismatch: conditional/tissue-specific knockouts were required to generate a viable, phenotypically informative postnatal model. The sheep OBSL1 model, by contrast, is a naturally occurring, viable (in appropriate genotype/zygosity) large-animal model that may better approximate the human postnatal skeletal phenotype, though comparative fidelity has not been formally characterized against the human 3-M radiographic signature.

Summary Table: Suggested Ontology Bindings

Sources

• 3-M Syndrome – GeneReviews (NBK1481)
• OMIM #273750 – THREE M SYNDROME 1
• OMIM #612921 – THREE M SYNDROME 2
• OMIM #614205 – THREE M SYNDROME 3
• Orphanet: 3M syndrome (ORPHA2616)
• NORD: Three M Syndrome
• Hanson D et al., "The Primordial Growth Disorder 3-M Syndrome Connects Ubiquitination to the Cytoskeletal Adaptor OBSL1," Am J Hum Genet 2009, PMID 19481195 — PMC2694976
• Meyer R et al., "3-M syndrome: a growth disorder associated with IGF2 silencing," Endocr Connect 2013, PMID 24148222 — PMC3847915
• Maksimova N et al., "Clinical, molecular and histopathological features of short stature syndrome with novel CUL7 mutation in Yakuts," 2007 — PMC2652813
• "3-M syndrome: evolution of the phenotype over time," Ital J Pediatr, Dec 2025, PMID 41437277, DOI 10.1186/s13052-025-02172-8 — PMC12838503
• "Establishment of the 3M syndrome animal model in CCDC8 knockout mice," Mol Biomed 2023, PMID 37574524 — PMC10423707
• "Longitudinal skeletal growth and growth plate morphological characteristics of chondro-tissue specific CUL7 knockout mice," PMID 38367951 — ScienceDirect
• "Molecular basis of a new ovine model for human 3M syndrome-2," BMC Genomic Data 2020 — Springer; PMC7493961
• Aldhoon-Hainerová I et al., "Gonadal Failure in a Male With 3-M Syndrome," JCEM Case Rep 2024, PMID 38847008 — PMC11154130
• "Chinese patients with 3M syndrome: clinical manifestations and two novel pathogenic variants," Front Genet 2023 — Frontiers
• "3-M syndrome: a novel CUL7 mutation associated with respiratory distress and a good response to GH therapy" — PMC4418346
• "3-M syndrome associated with growth hormone deficiency: 18 year follow-up of a patient," Ital J Pediatr 2013 — PMC3608257
• "Prenatal diagnosis and preimplantation genetics testing of 3M syndrome in a Chinese family with novel biallelic variants of CUL7" — PMC10767403
• Society for Endocrinology, "Loss of the Golgi localised E3 ubiquitin ligase containing Cullin 7 in 3-M syndrome leads to reduced cell proliferation and reduced IGF1 mediated activation of Akt" — Endocrine Abstracts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.